1. Stewart BW, Wild CP. World Cancer Report 2014. Geneva, Switzerland: 444-465.
2. Hahn NM. Cancer of the Bladder and Urinary Tract. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 20e. McGraw Hil, 2018. Accessed April 24, 2022. [
Article]
3. Pulciani S, Santos E, Lauver AV, et al. Oncogenes In Human Tumor Cell Lines: Molecular Cloning Of A Transforming Gene From Human Bladder Carcinoma Cells. Proc Natl Acad Sci USA 1982; 79(9): 2845-9. [
DOI]
4. Sidransky D, Messing E. Molecular Genetics And Biochemical Mechanisms In Bladder Cancer. Oncogenes, Tumor Suppressor Genes, And Growth Factors. Urol Clin North Am 1992; 19(4): 629-39. [
PubMed]
5. Cooper GM, Hausman RE, Hausman RE. The Cell: A Molecular Approach, 8e, Sinauer Associates: Sunderland, MA, 2019: 713-777. [
Article]
6. Du J, Wang SH, Yang Q, et al. p53 Status Correlates With The Risk Of Progression In Stage T1 Bladder Cancer: A Meta-Analysis. World J Surg Onc 2016; 14: 137. [
DOI]
7. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 Tumor Suppressor Gene: Clues To Cancer Etiology And Molecular Pathogenesis. Cancer Res 1994; 54(18): 4855-78. [
PubMed]
8. Joerger AC, Fersht AR. Structural Biology Of The Tumor Suppressor p53. Annu Rev Biochem 2008; 77: 557-82. [
DOI]
9. Rizzotto D, Englmaier L, Villunger A. At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity. Int J Mol Sci 2021; 22(19): 10883. [
DOI]
10. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50(1): 7-33. [
DOI]
11. Bargonetti J, Manfredi JJ. Multiple Roles Of The Tumor Suppressor p53. Curr Opin Oncol 2002; 14(1): 86-91. [
DOI]
12. Aljabery F, Shabo I, Gimm O, et al. The Expression Profile of p14, p53 and p21 in Tumour Cells Is Associated With Disease-Specific Survival and the Outcome Of Postoperative Chemotherapy Treatment In Muscle-Invasive Bladder Cancer. Urol Oncol 2018; 36(12): 530.e7-530.e18. [
DOI]
13. Heim S, Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 4e. WileyBlackwell, 2015: 113-145. [
Article]
14. Goebell PJ, Groshen SG, Schmitz-Drager BJ, et al. p53 Immunohistochemistry In Bladder Cancer--A New Approach To An Old Question. Urol Oncol 2010; 28(4): 377-88. [
DOI]
15. Nakopoulou L, Constantinides C, Papandropoulos J, et al. Evaluation of Overexpression of p53 Tumor Suppressor Protein In Superficial And Invasive Transitional Cell Bladder Cancer: Comparison With DNA Ploidy. Urology 1995; 46(3): 334-40. [
DOI]
16. Wu CS, Pollack A, Czerniak B, et al. Prognostic Value of p53 In Muscle-Invasive Bladder Cancer Treated With Preoperative Radiotherapy. Urology 1996; 47(3): 305-10. [
DOI]
17. Fromont G, Roupret M, Amira N, et al. Tissue Microarray Analysis Of The Prognostic Value of E-cadherin, Ki67, p53, p27, survivin and MSH2 Expression In Upper Urinary Tract Transitional Cell Carcinoma. Eur Urol 2005; 48(5): 764-70. [
DOI]
18. Hodgson A, Xu B, Downes MR. p53 Immunohistochemistry In High-Grade Urothelial Carcinoma Of The Bladder Is Prognostically Significant. Histopathology 2017; 71(2): 296-304. [
DOI]
19. Alexander RE, Williamson SR, Richey J, et al. The Expression Patterns of p53 and p16 and an Analysis Of A Possible Role Of HPV In Primary Adenocarcinoma Of The Urinary Bladder. PLoS One 2014; 9(4): e95724. [
DOI]
20. Horstmann M, Witthuhn R, Falk M, et al. Gender-Specific Differences In Bladder Cancer: A Retrospective Analysis. Gend Med 2008; 5(4): 385-94. [
DOI]
21. Rafiemanesh H, Lotfi Z, Bakhtazad S, et al. The Epidemiological And Histological Trend Of Bladder Cancer In Iran. J Cancer Res Ther 2018; 14(3): 532-6. [
DOI]
22. Cheng L, Zhang S, Davidson DD, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 2009; 5(6): 843-57. [
Article]
23. Lutzeyer W, Rübben H, Dahm H. Prognostic Parameters In Superficial Bladder Cancer: An Analysis Of 315 Cases. J Urol 1982; 127(2): 250-2. [
DOI]
24. Prout Jr GR, Barton BA, Griffin PP, et al. Treated history of noninvasive grade 1 transitional cell carcinoma. 1992;148(5):1413-9. [
DOI]
25. Kurth K, Bouffioux C, Sylvester R, et al. MJEu. Treatment Of Superficial Bladder Tumors: Achievements And Needs. 2000; 37(Suppl. 3): 1-9. [
DOI]
26. Kiemeney LA, Moret NC, Witjes JA, et al. Familial Transitional Cell Carcinoma Among The Population Of Iceland. J Urol 1997; 157(5): 1649-51. [
PubMed]
27. SafariChaleshtori J, Moradi M T, Farokhi E, et al. Detection of mutations in exons 5-8 of the P53 gene in gastric cancer samples using PCR-SSCP in Chaharmahal va Bakhtiari province 2006-2007. J Shahrekord Univ Med Sci. 2009; 11(3): 61-69. [
Article]
28. Tetu B, Fradet Y, Allard P, et al. Prevalence And Clinical Significance of HER-2/neu, p53 and Rb Expression In Primary Superficial Bladder Cancer. J Urol 1996; 155(5): 1784-8. [
PubMed]
29. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM, et al. Prognostic Implications of p53 Gene Mutations In Bladder Tumors. J Urol 2003; 169(2): 492-9. [
DOI]
30. Levine AJ, Momand J, Finlay CA. The p53 Tumour Suppressor Gene. Nature 1991; 351(6326): 453-6. [
DOI]
31. Esrig D, Spruck 3rd CH, Nichols PW, et al. p53 Nuclear Protein Accumulation Correlates With Mutations In The p53 Gene, Tumor Grade, And Stage In Bladder Cancer. Am J Pathol 1993; 143(5): 1389-97. [
PubMed]
32. Asgari M, Noori S. P53 Over Expression In Transitional Cell Carcinoma Of Bladder. Razi J Med Sci 2002; 9(29): 250-4. (Persian) [
Article]
33. Saffari Chaleshtary J, Moradi Mt, Farrokhi E, et al. Study of P53 gene mutations in promoter and exons 2-4 and 9-11 in patient with gastric cancer by PCR-SSCP in Chaharmahal Va Bakhtiari province. Iranian South Medical Journal 2011; 14(4): 220-9. [
Article]
34. Goebell PJ, Groshen SG, Schmitz-Dräger BJ. p53 immunohistochemistry in bladder cancer-- a new approach to an old question. Urologic oncology 2010; 28(4): 377-88. [
DOI]
35. Papadogianni D, Soulitzis N, Delakas D, et al. Expression of p53 Family Genes In Urinary Bladder Cancer: Correlation With Disease Aggressiveness And Recurrence. Tumour Biol 2014; 35(3): 2481-9. [
DOI]
36. Wang ZP, Chen SY, Tian Y. Wild-type p53-Induced Phosphatase 1 Is A Prognostic Marker And Therapeutic Target In Bladder Transitional Cell Carcinoma. Oncol Lett 2017; 13(2): 875-80. [
DOI]
37. Zaker Hosseini M, Naeimi S, Moradinasab M, et al. Codon 72 Polymorphism of TP53 Gene in Cervical Biopsies with Abnormal Histology in Bushehr Province. Iran South Med J 2018; 21(1): 19-28. [
Article]